Diagnosis and referral of adults with suspected bony metastases

BMJ ◽  
2021 ◽  
pp. n98
Author(s):  
Samantha Downie ◽  
Elizabeth Bryden ◽  
Fergus Perks ◽  
A Hamish RW Simpson
Keyword(s):  
2012 ◽  
Vol 53 (11) ◽  
pp. 1730-1735 ◽  
Author(s):  
S.-C. Chan ◽  
H.-M. Wang ◽  
S.-H. Ng ◽  
C.-L. Hsu ◽  
Y.-J. Lin ◽  
...  

PEDIATRICS ◽  
1959 ◽  
Vol 23 (6) ◽  
pp. 1179-1191
Author(s):  
Robert E. Gross ◽  
Sidney Farber ◽  
Lester W. Martin

The treatment of patients with neuroblastoma does not lie solely in the province of a single specialty; it requires cooperation of pediatrician, surgeon, radiologist and tumor therapist. It is essential that they all be aware of the unique characteristics of this particular tumor if optimum results are to be obtained. The many factors found to influence the prognosis for a child with neuroblastoma are discussed. In those cases wherein there are no demonstrable metastases, the treatment of choice consists of total excision, followed by local x-ray irradiation; this has resulted in a cure rate of 88%. In those cases wherein total excision is not possible, partial surgical removal followed by x-ray irradiation and tumor chemotherapy has given a cure rate of 64%. In those cases where only biopsy has been performed, x-ray irradiation and chemotherapy has still given a salvage, with a cure rate of 38%. When there are metastases to the liver alone, about two-thirds of babies can be cured by x-ray therapy. Whenever bony metastases have appeared in any case, the prognosis is extremely poor, and it is rare for such an individual to survive, regardless of the form of therapy. An aggressive attack on neuroblastoma in infancy and childhood, combining sungeny, x-ray irradiation and tumor chemotherapy, has shown a progressive improvement in results. During the period 1950-1957, cure rates have risen to 36.7% for all patients entering the hospital, regardless of age of the patient on extent of the neoplasm. For babies under a year of age, cures have occurred in 56%, and if there were no demonstrable metastases to bone at the time of hospitalization, the cures have been 70%.


2009 ◽  
Vol 27 (21) ◽  
pp. 3459-3464 ◽  
Author(s):  
Jennifer R. Stark ◽  
Sven Perner ◽  
Meir J. Stampfer ◽  
Jennifer A. Sinnott ◽  
Stephen Finn ◽  
...  

Purpose Gleason grading is an important predictor of prostate cancer (PCa) outcomes. Studies using surrogate PCa end points suggest outcomes for Gleason score (GS) 7 cancers vary according to the predominance of pattern 4. These studies have influenced clinical practice, but it is unclear if rates of PCa mortality differ for 3 + 4 and 4 + 3 tumors. Using PCa mortality as the primary end point, we compared outcomes in Gleason 3 + 4 and 4 + 3 cancers, and the predictive ability of GS from a standardized review versus original scoring. Patients and Methods Three study pathologists conducted a blinded standardized review of 693 prostatectomy and 119 biopsy specimens to assign primary and secondary Gleason patterns. Tumor specimens were from PCa patients diagnosed between 1984 and 2004 from the Physicians' Health Study and Health Professionals Follow-Up Study. Lethal PCa (n = 53) was defined as development of bony metastases or PCa death. Hazard ratios (HR) were estimated according to original GS and standardized GS. We compared the discrimination of standardized and original grading with C-statistics from models of 10-year survival. Results For prostatectomy specimens, 4 + 3 cancers were associated with a three-fold increase in lethal PCa compared with 3 + 4 cancers (95% CI, 1.1 to 8.6). The discrimination of models of standardized scores from prostatectomy (C-statistic, 0.86) and biopsy (C-statistic, 0.85) were improved compared to models of original scores (prostatectomy C-statistic, 0.82; biopsy C-statistic, 0.72). Conclusion Ignoring the predominance of Gleason pattern 4 in GS 7 cancers may conceal important prognostic information. A standardized review of GS can improve prediction of PCa survival.


2020 ◽  
pp. 4709-4713
Author(s):  
Helen Hatcher

Benign bone tumours are common, usually asymptomatic, and discovered incidentally. Malignant primary bone tumours are uncommon but cause significant morbidity and mortality, particularly in adolescents and young adults. Bony metastases are the tumours most frequently seen in bone. Malignant bone tumours typically present with localized pain or swelling. With patients in whom the diagnosis is not clearly metastatic disease, determination of tumour size and extent is best achieved by magnetic resonance imaging, and bone biopsy is mandatory to establish a precise histological diagnosis. Osteosarcoma, chondrosarcoma, and Ewing sarcoma are the three commonest primary bone tumours. In determining management, the main clinical distinction is between localized and metastatic disease. Non-metastatic primary tumours are treated with surgery (when possible) and chemotherapy (osteosarcoma and Ewing sarcoma, sometimes chondrosarcoma). Symptomatic bony metastases are usually treated with external beam radiotherapy.


1976 ◽  
Vol 69 (6) ◽  
pp. 812-813 ◽  
Author(s):  
SURESH KUMARI
Keyword(s):  

1990 ◽  
Vol 104 (1) ◽  
pp. 43-44
Author(s):  
H. E. Christmas ◽  
R. P. Mills ◽  
R. Davies

AbstractWe report a case of nasopharyngeal squamous carcinoma complicated by diabetes insipidus and hypercalcaemia. As there was no evidence of bony metastases we conclude that this latter finding was due to a humoral factor produced by the tumour. The management of these problems is discussed.


2016 ◽  
Vol 38 (7) ◽  
pp. e263-e266 ◽  
Author(s):  
Laura L. Hayes ◽  
Adina Alazraki ◽  
Karen Wasilewski-Masker ◽  
Richard A. Jones ◽  
David A. Porter ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document